5 completed, 3 recruiting, 1 active not recruiting, 1 terminated. 10 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 5, Recruiting 3, Active not recruiting 1, Terminated 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Ovarian Carcinosarcoma: new trials by email Literature Review of Ovarian Carcinosarcoma trials Research Report on Ovarian Carcinosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer VLS-1488 - Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary | Phase 1 / Phase 2 | Recruiting | Volastra Therapeutics, Inc. | 200 | 2023-10-18 | 2025-11-04 |
| EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma Eribulin Mesylate, Pembrolizumab - Ovarian Carcinosarcoma, Uterine Carcinosarcoma | Phase 2 | Completed | Australia New Zealand Gynaecological Oncology Group | 13 | 2023-05-22 | 2026-08-06 |
| APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion Bevacizumab, Biopsy, Biospecimen Collection - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 60 | 2023-04-27 | 2026-03-23 |
| Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib Niraparib, Niraparib + TSR-042 (Dostarlimab), Chemotherapy Drugs - Ovarian Carcinosarcoma, Endometrial Carcinosarcoma | Phase 2 / Phase 3 | Recruiting | ARCAGY/ GINECO GROUP | 138 | 2020-07-15 | 2026-09-09 |
| Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Paclitaxel, TAK228 - Ovarian Cancer, Ovarian Neoplasms | Phase 2 | Completed | Imperial College London | 134 | 2018-09-21 | 2024-09-20 |
| LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas Aldesleukin, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1 - Bone Sarcoma, Dedifferentiated Chondrosarcoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2018-04-27 | 2026-11-10 |
| MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Bevacizumab, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Terminated | Mayo Clinic | 17 | 2015-03-13 | 2025-12-11 |
| Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Bevacizumab, Temsirolimus - Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 252 | 2009-09-08 | 2019-01-25 |
| Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer Avastin, Paclitaxel, Cisplatin - Advanced Ovarian Carcinoma, Primary Peritoneal Carcinoma | Phase 2 | Completed | University of Oklahoma | 20 | 2007-07-01 | 2017-07-02 |
| Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma ziv-aflibercept - Fallopian Tube Cancer, Female Reproductive Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 63 | 2006-09-01 | 2015-12-07 |
Ovarian Neoplasms (6) · Fallopian Tube Neoplasms (5) · Triple Negative Breast Neoplasms (2) · Bone Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Ovarian Epithelial (1) · Chromosomal Instability (1) · Endometrial Neoplasms (1) · Giant Cell Tumor of Bone (1) · Histiocytoma, Malignant Fibrous (1) · Osteosarcoma (1) · Sarcoma (1) · Somatostatinoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Thyroid Carcinoma, Anaplastic (1)
Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Genital Diseases (8) · Genital Diseases, Female (8) · Genital Neoplasms, Female (8) · Neoplasms (8) · Neoplasms by Site (8) · Urogenital Diseases (8) · Urogenital Neoplasms (8) · Adnexal Diseases (7) · Endocrine Gland Neoplasms (7) · Endocrine System Diseases (7) · Gonadal Disorders (7) · Ovarian Diseases (7) · Fallopian Tube Diseases (5)
Bevacizumab (4) · Disulfides (3) · Immunoglobulin G (3) · Paclitaxel (3) · pembrolizumab (2) · Antineoplastic Agents (1) · Biopsy (1) · CTLA-4 Antigen (1) · Cisplatin (1) · Cyclophosphamide (1) · Doxorubicin (1) · Gemcitabine (1) · Ipilimumab (1) · Nivolumab (1) · Sirolimus (1)
National Cancer Institute (NCI) (2) · ARCAGY/ GINECO GROUP (1) · Australia New Zealand Gynaecological Oncology Group (1) · Imperial College London (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Roswell Park Cancer Institute (1) · University of Oklahoma (1) · Volastra Therapeutics, Inc. (1)
United States (7) · Canada (3) · United Kingdom (2) · Australia (1) · France (1) · Germany (1) · Italy (1) · Spain (1)
Amir A Jazaeri (1) · Amit Oza (1) · Clare Scott, AM MB BS PhD (1) · D. Scott McMeekin, MD (1) · Emese Zsiros (1) · Evanthia Galanis, M.D. (1) · Henry Pitot (1) · Jonathan Krell (1)
PMID 25318437, PMID 25488966, PMID 34986897, PMID 35382842, PMID 37702588
N01CM62201 (2), N01CM62203 (2), N01CM62209 (2), N01CM00032 (1), N01CM00038 (1), N01CM00039 (1), N01CM00070 (1), N01CM00071 (1), N01CM00099 (1), N01CM00100 (1), N01CM62204 (1), N01CM62205 (1), N01CM62206 (1), N01CM62207 (1), N01CM62208 (1)